|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-8-15
|
|
pubmed:abstractText |
The optimal salvage therapy for recurrent ovarian carcinoma has not been clearly established. Response to second-line chemotherapy is low, with a short median survival (8.8-15 months). We investigated the effect of an aggressive approach consisting of surgery followed by intraperitoneal drug delivery and local hyperthermia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-8916
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
120-6
|
|
pubmed:dateRevised |
2008-12-12
|
|
pubmed:meshHeading |
pubmed-meshheading:11504363-Adult,
pubmed-meshheading:11504363-Aged,
pubmed-meshheading:11504363-Antineoplastic Agents,
pubmed-meshheading:11504363-Carcinoma,
pubmed-meshheading:11504363-Chemotherapy, Cancer, Regional Perfusion,
pubmed-meshheading:11504363-Cisplatin,
pubmed-meshheading:11504363-Disease-Free Survival,
pubmed-meshheading:11504363-Feasibility Studies,
pubmed-meshheading:11504363-Female,
pubmed-meshheading:11504363-Follow-Up Studies,
pubmed-meshheading:11504363-Humans,
pubmed-meshheading:11504363-Hyperthermia, Induced,
pubmed-meshheading:11504363-Middle Aged,
pubmed-meshheading:11504363-Mitomycin,
pubmed-meshheading:11504363-Neoplasm Recurrence, Local,
pubmed-meshheading:11504363-Ovarian Neoplasms,
pubmed-meshheading:11504363-Peritoneum,
pubmed-meshheading:11504363-Survival Analysis,
pubmed-meshheading:11504363-Treatment Outcome,
pubmed-meshheading:11504363-Tumor Markers, Biological
|
|
pubmed:articleTitle |
Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.
|
|
pubmed:affiliation |
Department of Surgery, National Cancer Institute, Milan, Italy. marcelloderaco@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
